216 related articles for article (PubMed ID: 32374045)
1. Predicting MGMT Promoter Methylation of Glioblastoma from Dynamic Susceptibility Contrast Perfusion: A Radiomic Approach.
Crisi G; Filice S
J Neuroimaging; 2020 Jul; 30(4):458-462. PubMed ID: 32374045
[TBL] [Abstract][Full Text] [Related]
2. Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma.
Lu Y; Patel M; Natarajan K; Ughratdar I; Sanghera P; Jena R; Watts C; Sawlani V
Magn Reson Imaging; 2020 Dec; 74():161-170. PubMed ID: 32980505
[TBL] [Abstract][Full Text] [Related]
3. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
[TBL] [Abstract][Full Text] [Related]
4.
Choi HJ; Choi SH; You SH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park CK; Park SH
AJNR Am J Neuroradiol; 2021 May; 42(5):853-860. PubMed ID: 33632732
[TBL] [Abstract][Full Text] [Related]
5. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
[TBL] [Abstract][Full Text] [Related]
6. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.
Li ZC; Bai H; Sun Q; Li Q; Liu L; Zou Y; Chen Y; Liang C; Zheng H
Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594
[TBL] [Abstract][Full Text] [Related]
7. The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated
Choi YS; Ahn SS; Lee HJ; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
AJNR Am J Neuroradiol; 2017 Aug; 38(8):1528-1535. PubMed ID: 28642265
[TBL] [Abstract][Full Text] [Related]
8. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H
J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
[TBL] [Abstract][Full Text] [Related]
9. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
10. Clinically Relevant Imaging Features for
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
AJNR Am J Neuroradiol; 2018 Aug; 39(8):1439-1445. PubMed ID: 30002055
[TBL] [Abstract][Full Text] [Related]
11. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
[TBL] [Abstract][Full Text] [Related]
12. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
13. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive O
Hajianfar G; Shiri I; Maleki H; Oveisi N; Haghparast A; Abdollahi H; Oveisi M
World Neurosurg; 2019 Dec; 132():e140-e161. PubMed ID: 31505292
[TBL] [Abstract][Full Text] [Related]
15. Development of A Radiomic Model for
Doniselli FM; Pascuzzo R; Agrò M; Aquino D; Anghileri E; Farinotti M; Pollo B; Paterra R; Cuccarini V; Moscatelli M; DiMeco F; Sconfienza LM
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203308
[TBL] [Abstract][Full Text] [Related]
16. Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas.
Lu J; Li X; Li H
Magn Reson Imaging; 2021 Nov; 83():189-195. PubMed ID: 34506909
[TBL] [Abstract][Full Text] [Related]
17. MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold.
Katsigiannis S; Grau S; Krischek B; Er K; Pintea B; Goldbrunner R; Stavrinou P
Neurosurgery; 2021 Mar; 88(4):E323-E329. PubMed ID: 33432978
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.
Kong DS; Kim ST; Kim EH; Lim DH; Kim WS; Suh YL; Lee JI; Park K; Kim JH; Nam DH
AJNR Am J Neuroradiol; 2011 Feb; 32(2):382-7. PubMed ID: 21252041
[TBL] [Abstract][Full Text] [Related]
19. MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas.
Korfiatis P; Kline TL; Coufalova L; Lachance DH; Parney IF; Carter RE; Buckner JC; Erickson BJ
Med Phys; 2016 Jun; 43(6):2835-2844. PubMed ID: 27277032
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
